<a href="https://www.fiercebiotech.com/biotech/orbimeds-sidewinder-slithers-toward-clinic-137m-series-b-antibody-drug-conjugates" hreflang="en">OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates</a>
fiercebiotech.com·Apr 7, 2026
Sidewinder Therapeutics has secured $137 million in a series B funding round from new investors to support its preparations for a clinical debut in 2027, three years after its initial series A backed by OrbiMed.
The key learning for you is that Sidewinder Therapeutics' successful $137 million series B funding round, backed by new investors, signals strong confidence in their pipeline and the potential impact of their upcoming 2027 clinical debut. This is a notable indicator for investment opportunities in biotech startups with promising clinical timelines and robust investor interest.